Table 4

Multivariate Cox regression analysis (in the subpopulation of Bev-treated patients)*
Overall survival Progression-free survival
HR 95% CI Wald’s p HR 95% CI Wald’s p
Group
XELIRI-Bev 1 1
FOLFIRI-Bev 0.842 0.587–1.207 0.35 0.949 0.682–1.321 0.76
Performance status
0 1 1
1–2 1.710 1.164–2.513 0.006 1.375 0.952–1.986 0.090
Number of organs involved
1 1 1
2 1.580 1.052–2.373 0.027 1.475 1.019–2.135 0.040
≥3 2.598 1.502–4.493 0.001 2.305 1.337–3.973 0.003
Osteopontin (OPN)
Low 1 1
High 1.632 1.116–2.387 0.012 1.467 1.044–2.060 0.027

*Both models remain the same whether continuous or binary variables of plasma concentrations of markers were used.

HR, hazard ratio; CI, confidence interval.

Pectasides et al.

Pectasides et al. BMC Cancer 2012 12:271   doi:10.1186/1471-2407-12-271

Open Data